FdaApplication
NDA 215206
Identifiers
- fda_app_no: NDA215206
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2021-09-28 |
Revenue by product
QULIPTA
| Period | Revenue |
|---|---|
| Q2 2026 | $350.0M |
| Q1 2026 | $296.0M |
| Q4 2025 | $288.0M |
| Q3 2025 | $288.0M |
| Q2 2025 | $267.0M |
| Q1 2025 | $193.0M |
| Q4 2024 | $201.0M |
| Q3 2024 | $176.0M |
| Q2 2024 | $150.0M |
| Q1 2024 | $131.0M |
| Q4 2023 | $114.0M |
| Q3 2023 | $132.0M |
| Q2 2023 | $96.0M |
| Q1 2023 | $66.0M |
| Q4 2022 | $52.0M |
| Q3 2022 | $62.0M |
| Q2 2022 | $33.0M |
| Q1 2022 | $11.0M |
| Q4 2021 | $0.0M |
| Q3 2021 | $0.0M |
| Q2 2021 | $0.0M |
| Q1 2021 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| QULIPTA | ATOGEPANT | 10MG | TABLET;ORAL |
| QULIPTA | ATOGEPANT | 60MG | TABLET;ORAL |
| QULIPTA | ATOGEPANT | 30MG | TABLET;ORAL |
3 products